BDNF and myeloid sarcoma: A reduced axonal energy metabolism, glutamate toxicity, and decreased brain-derived neurotrophic factor (BDNF) levels are suspected to be involved in the widespread axonal degeneration that underlies progression in progressive MS [5–7].